FDA warns Fancy Meds that its compounded semaglutide and tirzepatide website claims are false or misleading.
What happened
FDA reviewed website content at https://fancymeds.com in August 2025; there was no inspection. The site offered compounded semaglutide and tirzepatide and said they have the same active ingredient as Ozempic, Wegovy, Mounjaro and Zepbound. FDA says compounded drugs are not FDA-approved, so those claims imply equivalence with approved products and are false or misleading.
What FDA found
FDA says the website claims are false or misleading, making the drugs 'misbranded' (false or misleading labeling).
FDCA section 502(a) [21 U.S.C. § 352(a)]FDA says advertising or promotion of a compounded drug is also false or misleading when it implies the product is the same as an FDA-approved drug.
FDCA section 502(bb) [21 U.S.C. § 352(bb)]FDA says the misbranded drugs were introduced or delivered for introduction into interstate commerce.
FDCA section 301(a) [21 U.S.C. § 331(a)]FDA says receiving misbranded drugs and delivering them, or offering to deliver them, also violates the law.
FDCA section 301(c) [21 U.S.C. § 331(c)]
What FDA wants
FDA tells Fancy Meds to take immediate action, including stopping the cited language, and to respond within 15 working days with the steps taken, supporting documents, and how it will prevent recurrence. If it cannot finish in that time, it must explain the delay and when it will finish.
Who should pay attention
- telehealth sellers of compounded semaglutide and tirzepatide
- compounding pharmacies and their marketing teams
- companies comparing their drugs to FDA-approved brand products
This is a summary. Read the original letter on fda.gov.